Low p-vals are great to see; they're an important piece of information on an endpoint's evaluation. They are not sufficient on their own. They're based on the difference in mean change in relation to the observed SD. His point was that clinical impact is not entirely dependent on either, so we (and regulators) need more info on what constitutes a clinically meaningful result. That itself can be tricky, when dealing with brain volumes. Brain volumes decline naturally with age, and do not necessarily correlate with cognitive declines (similar to amyloid burden, as an example). Hopefully our brain volume data will correlate in our trial study.
Market Data 
Markets 
AI
